Literature DB >> 35574994

Nlrp3 inflammasome activation in macrophages suffices for inducing autoinflammation in mice.

Ulrika C Frising1,2, Silvia Ribo1,2, M Giulia Doglio1,2, Bernard Malissen3, Geert van Loo2,4, Andy Wullaert1,2,5.   

Abstract

Cryopyrin-associated periodic syndromes (CAPS) are a spectrum of autoinflammatory disorders caused by gain-of-function NLRP3 mutant proteins that form hyperactive inflammasomes leading to overproduction of the pro-inflammatory cytokines IL-1β and IL-18. Expressing the murine gain-of-function Nlrp3A350V mutant selectively in neutrophils recapitulates several autoinflammatory features of human CAPS, but the potential contribution of macrophage inflammasome hyperactivation to CAPS development is poorly defined. Here, we show that expressing Nlrp3A350V in macrophages is sufficient for driving severe multi-organ autoinflammation leading to perinatal lethality in mice. In addition, we show that macrophages contribute to autoinflammation also in adult mice, as depleting macrophages in mice ubiquitously expressing Nlrp3A350V significantly diminishes splenic and hepatic IL-1β production. Interestingly, inflammation induced by macrophage-selective Nlrp3A350V expression does not provoke an influx of mature neutrophils, while neutrophil influx is still occurring in macrophage-depleted mice with body-wide Nlrp3A350V expression. These observations identify macrophages as important cellular drivers of CAPS in mice and support a cooperative cellular model of CAPS development in which macrophages and neutrophils act independently of each other in propagating severe autoinflammation.
© 2022 The Authors.

Entities:  

Keywords:  Nlrp3; cryopyrin-associated periodic syndromes; inflammasome; interleukin-1β; macrophage

Mesh:

Substances:

Year:  2022        PMID: 35574994      PMCID: PMC9253760          DOI: 10.15252/embr.202154339

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   9.071


  34 in total

1.  Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever.

Authors:  H M Hoffman; A A Wanderer; D H Broide
Journal:  J Allergy Clin Immunol       Date:  2001-10       Impact factor: 10.793

2.  Restoration of p53 function leads to tumour regression in vivo.

Authors:  Andrea Ventura; David G Kirsch; Margaret E McLaughlin; David A Tuveson; Jan Grimm; Laura Lintault; Jamie Newman; Elizabeth E Reczek; Ralph Weissleder; Tyler Jacks
Journal:  Nature       Date:  2007-01-24       Impact factor: 49.962

3.  Comparative analysis of the efficiency and specificity of myeloid-Cre deleting strains using ROSA-EYFP reporter mice.

Authors:  Clare L Abram; Gray L Roberge; Yongmei Hu; Clifford A Lowell
Journal:  J Immunol Methods       Date:  2014-05-22       Impact factor: 2.303

4.  De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases.

Authors:  Ivona Aksentijevich; Miroslawa Nowak; Mustapha Mallah; Jae Jin Chae; Wendy T Watford; Sigrun R Hofmann; Leonard Stein; Ricardo Russo; Donald Goldsmith; Peter Dent; Helene F Rosenberg; Frances Austin; Elaine F Remmers; James E Balow; Sergio Rosenzweig; Hirsh Komarow; Nitza G Shoham; Geryl Wood; Janet Jones; Nadira Mangra; Hector Carrero; Barbara S Adams; Terry L Moore; Kenneth Schikler; Hal Hoffman; Daniel J Lovell; Robert Lipnick; Karyl Barron; John J O'Shea; Daniel L Kastner; Raphaela Goldbach-Mansky
Journal:  Arthritis Rheum       Date:  2002-12

5.  Macrophages, rather than DCs, are responsible for inflammasome activity in the GM-CSF BMDC model.

Authors:  Ziv Erlich; Inbar Shlomovitz; Liat Edry-Botzer; Hadar Cohen; Daniel Frank; Hanqing Wang; Andrew M Lew; Kate E Lawlor; Yifan Zhan; James E Vince; Motti Gerlic
Journal:  Nat Immunol       Date:  2019-02-11       Impact factor: 25.606

6.  Granulocyte-Monocyte Progenitors and Monocyte-Dendritic Cell Progenitors Independently Produce Functionally Distinct Monocytes.

Authors:  Alberto Yáñez; Simon G Coetzee; Andre Olsson; David E Muench; Benjamin P Berman; Dennis J Hazelett; Nathan Salomonis; H Leighton Grimes; Helen S Goodridge
Journal:  Immunity       Date:  2017-11-21       Impact factor: 31.745

7.  Nlrp3 inflammasome activation in macrophages suffices for inducing autoinflammation in mice.

Authors:  Ulrika C Frising; Silvia Ribo; M Giulia Doglio; Bernard Malissen; Geert van Loo; Andy Wullaert
Journal:  EMBO Rep       Date:  2022-05-16       Impact factor: 9.071

8.  Cutting edge: IL-6 is a marker of inflammation with no direct role in inflammasome-mediated mouse models.

Authors:  Matthew D McGeough; Carla A Pena; James L Mueller; Derek A Pociask; Lori Broderick; Hal M Hoffman; Susannah D Brydges
Journal:  J Immunol       Date:  2012-08-17       Impact factor: 5.422

9.  Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies.

Authors:  Susannah D Brydges; Lori Broderick; Matthew D McGeough; Carla A Pena; James L Mueller; Hal M Hoffman
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

10.  Deletion of a Csf1r enhancer selectively impacts CSF1R expression and development of tissue macrophage populations.

Authors:  Rocío Rojo; Anna Raper; Derya D Ozdemir; Lucas Lefevre; Kathleen Grabert; Evi Wollscheid-Lengeling; Barry Bradford; Melanie Caruso; Iveta Gazova; Alejandra Sánchez; Zofia M Lisowski; Joana Alves; Irene Molina-Gonzalez; Hayk Davtyan; Rebecca J Lodge; James D Glover; Robert Wallace; David A D Munro; Eyal David; Ido Amit; Véronique E Miron; Josef Priller; Stephen J Jenkins; Giles E Hardingham; Mathew Blurton-Jones; Neil A Mabbott; Kim M Summers; Peter Hohenstein; David A Hume; Clare Pridans
Journal:  Nat Commun       Date:  2019-07-19       Impact factor: 14.919

View more
  1 in total

1.  Nlrp3 inflammasome activation in macrophages suffices for inducing autoinflammation in mice.

Authors:  Ulrika C Frising; Silvia Ribo; M Giulia Doglio; Bernard Malissen; Geert van Loo; Andy Wullaert
Journal:  EMBO Rep       Date:  2022-05-16       Impact factor: 9.071

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.